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Background: Single-item assessments have been the most often-used measures in National Cancer Institute (NCI)
cancer control clinical trials, but normative data are not available. Our objective was to examine the normative data
and clinically significant effect sizes for single-item numerical linear analogue self-assessment (LASA) scale for overall
quality of life (QOL).
Methods: We analyzed baseline data from 36 clinical trials and 6 observational studies with various populations,
including healthy volunteers, cancer trial patients (patients with advanced incurable cancer or patients receiving
treatment with curative intent) and hospice patients as well as their caregivers. The overall QOL LASA was rated 0
(as bad as it can be) to 10 (as good as it can be). We calculated the summary statistics and the proportion of
patients reporting a clinically meaningful deficit (CMD) of a score equal to 5 or less on the 0–10 scale.
Results: In total, for the collective sample of 9,295 individuals, the average overall QOL reported was 7.39 (SD = 2.11)
with a markedly skewed distribution with roughly 17% reporting a score of 5 or below indicating a clinically significant
deficit in overall QOL. Hospice patients report a much worse average score of 5.7 upon entry to hospice; hospice
caregivers average 7.4. Cancer patients vary within these two extremes with most patients averaging in the 7’s on the
0–10 scale (range, 0 to 10 p-value < 0.0001). Men and women’s QOL distributions were virtually identical (with average of
7.6 vs. 7.5, p-value = 0.046). Overall QOL was weakly related to performance status with a Spearman correlation coefficient
of −0.29 (p-value < 0.0001). Overall QOL was related to tumor response (p-value = 0.0094), i.e. patients with a full or partial
response reported a CMD in 11.4% of cases compared to 14.4% among those with stable disease and 18.5% among
those with disease progression. Data missingness was high for performance status and tumor response associations.
Conclusions: This study provides the normative data for cancer patients and healthy volunteers for overall QOL using
the LASA. These can serve as benchmarks for future studies and inform clinical practice decision-making.
Keywords: Quality of life, Measurement, LASA, Validation, Single item, Linear analog scale, Patient-reported outcomes,
PROs, QOLBackground
Patient-reported outcomes (PROs) are increasingly be-
coming the focus of research and clinical practice [1,2]. A
major challenge in the use of PROs is the practical consid-
eration of the number of items that can be asked [3]. Con-
siderable evidence has been generated to demonstrate the
value of simple single-item PRO assessments for describing* Correspondence: jsloan@mayo.edu
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unless otherwise stated.the effects of disease and treatment in cancer and other
diseases [4-6]. Single-item assessments in fact have been
the most often-used measures in National Cancer Institute
(NCI) cancer control clinical trials [7,8]. The purpose of
this manuscript was to present normative data for a spe-
cific set of single item PRO measures that have been used
in numerous clinical trials and clinical practice settings so
as to serve as a reference resource.
Linear Analogue Self Assessment (LASA) items have
been validated as general measures of global QOL dimen-
sional constructs in numerous settings [9-13]. The acronymhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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has come to be associated with simple single-item PRO
measures in clinical research. This is partially due to the
wide application of these simple measures and the ready
acceptance by clinical researchers and clinicians. These
single-item assessments have become the most-used as-
sessment in all NCI-sponsored cancer control studies
[8]. Single-item tools are in widespread use, for example
JCAHO has mandated that single-item pain assessments
be completed at the time of every clinical intake for insti-
tutions to maintain accreditation [14]. The incorporation
of these requirements into clinical practice presumes
patient care has improved although the evidence is in-
consistent [15]. Recently, a PRO Outcome Measurement
System (PROMIS) paper compared a single-item pain
measure to a longer assessment and indicated that the two
were psychometrically similar but complimentary [16].
This would seem to indicate that there is a place for both
in the clinical trials armamentarium.
The advantages of the LASA include brevity and mini-
mized burden for both the patient and the clinical or
research system. Sloan and colleagues explored the ad-
vantages and disadvantages of single versus multiple item
approaches extensively [1] and have further demonstrated
that where an indication of clinically significant deficits is
the goal of assessment, the LASAs are superior to longer
multi-item scales. This is in part due to the LASA allow-
ing a patient to make the gestalt combination for sub-
constructs rather than a predetermined metric formula
derived empirically from a factor analysis for example
[3]. Trusting that the patient has this capability is a
key assumption to success. Whatever a patient says
their QOL is, that is what it is. Some psychometric
analyses assume that the patient has to be fooled into
providing an accurate score or that they may give an
“inaccurate score”. This is condescending and paternalistic
in the extreme. As a triage screening or trigger, an indi-
vidual LASA has the most obvious application. Also, the
brevity allows for routine application in clinical settings
where a longer tool would be economically and temporally
prohibitive.
The disadvantages of the LASA include a lack of detail
about the deficit indicated by the single item. Others have
pointed to a lack of capability to obtain a measure of reli-
ability for a single item. However, as demonstrated by
Cleeland, if the construct being measured is valid and
understandable to the subject, then unidimensional reli-
ability is automatically present [17,18]. Furthermore, re-
cent research has indicated that reliability for single-items
can indeed be measured by using correction for attenu-
ation or factor analysis [19].
The LASA have become the focus of a specific line of
research into prognostic factors for survival. Specifically,
single item measures of overall QOL and fatigue havebeen seen to be prognostic for survival in multiple disease
groups [1,20-22].
Typically, LASAs are scored on a 0 to 10 scale. Ini-
tially a true linear analogue (i.e. a line) was presented to
patients who were asked to then place an X on the line
to represent their score. This had the benefit of producing
a “continuous” variable, but was arduous in terms of scor-
ing, as staff would have to use a ruler to measure the score
on each item. Research indicated that patients tended to
clump around the middle and quartiles of the line so that
the true measurement accuracy that was being provided
was realistically a five-point scale with errors around each
point. Subsequent LASAs hence used a 0–4 or 0–10 nu-
merical response scale (NRS). In some papers one will see
NRS instead of LASA for a label to be psychometrically
precise. The use of the 0–10 scale was demonstrated by
Norman et al. to have advantages over other alternatives,
although 0–4, 1–7, 1–5 and other response scales have all
been employed [23]. A linear transformation of any such
scaling can be used to translate all scores onto a 0–100
point scale.
A score 50 or below on the transformed 0–100 scale is
indicative of a need for immediate exploration and inter-
vention for the QOL deficit [4,24]. Due to these findings,
the NCCTG and subsequently the Alliance for Clinical
Trials in Oncology (Alliance) decided to include LASA
measures for overall QOL and fatigue in all future phase
II and phase III clinical trials as an independent prog-
nostic factor independent of performance status. Our
study objective was to analyze and present normative
data for LASA measures from various patient and con-
trol populations.
Methods
This paper presents a series of normative data for over-
all QOL LASA scale (Additional file 1) drawn from dif-
ferent populations ranging from healthy volunteers to
hospice patients. In total, baseline QOL LASA data
from 36 clinical trials and 6 observational studies are
included (Table 1). The reference indicated for each
study was either a published manuscript, a protocol, an
abstract or unpublished dataset as indicated. Healthy
NCCTG volunteers (54) provided LASA data via a sur-
vey at a semi-annual meeting. Mayo physician and
residents data is drawn from a survey. Please refer to
Additional file 2 for the details about where each sample
was obtained.
Simple summary statistics (means, standard deviations)
are the primary analytical tool for this work. Correlation
between the LASA and other measures/demographics was
accomplished via correlation coefficients. We compared
LASA scores across subpopulations by Fisher’s exact tests
for categorical variables and Kruskal-Wallis testing for
continuous variables.
Table 1 Data sources, population type, summary statistics for overall QOL
Patient category N Mean Median Minimum Maximum Standard deviation
Advanced cancer 120 7.26 8.10 0.20 9.70 2.31
Brain cancer 26 6.46 7.00 2.00 9.00 1.88
Breast cancer 296 7.77 8.20 1.40 10.00 1.84
Lung cancer 1155 7.25 7.80 0.00 10.00 2.10
Colon cancer −2 Wks Post Surgery (Colectomy) 388 7.57 8.00 1.50 10.00 1.80
Colon cancer-Pre Surgery (Colectomy) 403 8.06 8.50 2.00 10.00 1.75
GI cancer 2409 7.74 8.30 0.00 10.00 1.86
GU cancer 180 8.29 9.00 2.40 10.00 1.61
Gynecologic cancer 117 7.83 8.20 1.80 10.00 1.75
Head and neck cancer 254 7.24 7.80 0.00 10.00 2.27
Hematologic cancer 32 7.33 7.70 1.70 9.30 2.03
Lymphatic cancer 8 7.21 8.45 3.20 9.20 2.51
Multiple site cancer 14 8.02 8.00 6.00 10.00 1.56
Musculoskeletal site cancer 18 6.68 7.55 1.80 10.00 2.78
Neurologic cancer 214 7.42 8.00 1.00 10.00 1.90
Other cancer 52 7.91 8.80 1.00 10.00 2.34
Lung cancer- Mayo study 529 7.03 7.00 0.00 10.00 2.18
Lung cancer - Mayo study 6 months post diagnosis 1409 7.05 7.60 0.00 10.00 2.40
Skin cancer 7 7.59 7.90 5.90 9.40 1.17
Unknown site cancer 29 6.60 7.00 2.10 10.00 2.25
Healthy NCCTG volunteers 54 8.31 9.00 5.00 10.00 1.19
Hospice caregivers 53 7.44 7.50 3.75 10.00 1.74
Hospice 52 5.89 5.75 2.00 9.75 2.03
Minnesota medical students 543 7.16 7.00 1.00 10.00 1.76
Mayo physicians 460 7.30 7.00 1.00 10.00 1.69
Mayo residents 295 6.46 7.00 1.00 10.00 1.91
GI, gastroenterological; GU, genitourinary; NCCTG, North central chapter treatment group.
Distributions for the various cohorts of Table 1 are displayed in Figures 2 and 3.
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In total, for the collective sample of 9,295 individuals, the
average overall QOL reported was 7.39 (SD = 2.11) with
an overall distribution displayed in Figure 1. The distribu-
tion is markedly skewed with roughly 17% reporting a
score of 5 or below indicating a clinically significant deficit
in overall QOL. Distributions for the various cohorts of
Table 1 are displayed in Figures 2 and 3. Comparison of
overall QOL scores for select groups is shown in Figure 4.
Healthy individuals average above 8.3 (SD = 1.2) on the
0–10 scale and rarely report a score of 5 or below indi-
cating a clinical deficit (Tables 1 and 2). Hospice patients
report a much worse average score of 5.7 upon entry to
hospice, although it has been seen that their QOL will im-
prove after hospice care has been initiated [25]. Hospice
caregivers average 7.4. Cancer patients vary within these
two extremes with most patients averaging in the 7’s on the
0–10 scale. Health care professionals score on average al-
most as bad as their patients. In particular, Mayo Physiciansand Minnesota Medical students average 7.3 while resi-
dents averaged 6.5. The full range of the scale was reported
by almost all cohorts except for healthy individuals, hospice
caregivers and skin cancer patients.
Table 2 differentiates patient cohorts by the propor-
tion of patients reporting a clinically meaningful deficit
(CMD) of a score equal to 5 or less. This CMD is related
to a relative doubling for the risk of death [1]. Healthy
volunteers rarely (2%) reported a clinically significant
deficit. Hospice patients upon entry had the highest
prevalence (42%) of clinically significant deficits in over-
all QOL.
In terms of cancer site, lung, brain, musculoskeletal,
metastatic cancer, head and neck and lymphatic cancers
had between 20-33% with CMD in overall QOL. All
other cancer cohorts reported lower incidence rates of
CMD in overall QOL. It was notable that 28% of Mayo
residents, 13% of Mayo physicians and 15% of MN med-
ical students reported CMDs in QOL.
Figure 1 QOL scores were not available for 134 patients. Distribution of overall QOL score, N=9,161.
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selected demographics. Overall QOL on average de-
clined slightly with increased age, but only one seventh
of a standard deviation or a 7% increase in the per-
centage reporting a CMD in overall QOL (Table 3).
Men and women’s overall QOL distributions were vir-
tually identical (Table 4). When examining data separ-
ately from cancer treatment trials vs. observational
studies, differences were noted by age in treatment tri-
als, but not observational studies (Additional file 3).
Most data for gender came from cancer treatmentFigure 2 Error bars indicate standard deviation; medians are indicate
QOL for individual studies.trials, which showed identical scores in men and women
(Additional file 3); few data from observational studies
were available that showed some gender differences
(Additional file 4).
Overall QOL was weakly related to performance status
with a Spearman correlation coefficient of −0.29 indicating
that people with lower performance status tended to have
worse overall QOL (Table 5). Roughly 14% of patients with
performance status 0 or 1 reported a CMD compared to
58% reporting a CMD among patients with a performance
status 2 or worse.d by the horizontal lines with in each graphic. Boxplots of Overall
Figure 3 Error bars indicate standard deviation; medians are indicated by the horizontal lines with in each graphic. Boxplots of Overall
QOL for Patient Categories.
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quent tumor response (Table 6; p = 0.0094). Patients with a
full or partial response reported a CMD at baseline in
11.4% of cases compared to 14.4% among those with stable
disease and 18.5% among those with tumor progression.
Discussion
This paper provides a series of normative data drawn from
multiple sources for the simple single-item measure of
overall QOL that has been used in numerous clinical
trials, observational research and clinical practice settings.Figure 4 Error bars indicate standard deviation. Mean Overall QOL scoThe overall QOL item differentiates across healthy popu-
lations and various patient populations in terms of average
values and the incidence of CSDs reported.
A key finding is that overall QOL is different from per-
formance status. This result has been demonstrated previ-
ously in individual studies [3,4,26], but was demonstrated
here to be consistent across study populations. Similarly,
the relationship between tumor response in cancer pa-
tients and QOL is weak, as reported previously in a study
of 989 metastatic colorectal cancer [27]. For example,
neither baseline QOL nor changes in QOL indicated ares.
Table 2 Incidence of clinically significant deficits in QOL for each cohort
Cohorts QOL score on 0–10 scale N (%)
Missing <=5 >5 to <8 8-10 Total
Advanced cancer 7 25 (21%) 30 (25%) 65 (54%) 120
Brain cancer 0 8 (31%) 11 (42%) 7 (27%) 26
Breast cancer 0 27 (9%) 94 (32%) 175 (59%) 296
Clinical trial lung cancer 0 236 (20%) 350 (30%) 569 (49%) 1155
Colon cancer pts-2 wks post surgery (Colectomy) 63 67 (17%) 118 (30%) 203 (52%) 388
Colon cancer pts-pre surgery (Colectomy) 48 58 (14%) 85 (21%) 260 (65%) 403
GI cancer 0 287 (12%) 682 (28%) 1440 (60%) 2409
GU cancer 0 14 (8%) 41 (23%) 125 (69%) 180
Gynecologic cancer 0 14 (12%) 35 (30%) 68 (58%) 117
Head and neck cancer 0 54 (21%) 78 (31%) 122 (48%) 254
Hematologic cancer 0 4 (13%) 13 (41%) 15 (47%) 32
Lymphatic cancer 0 2 (25%) 1 (13%) 5 (63%) 8
Multiple site cancer 0 0 (0%) 5 (36%) 9 (64%) 14
Musculoskeletal site cancer 0 6 (33%) 5 (28%) 7 (39%) 18
Neurologic cancer 0 25 (12%) 75 (35%) 114 (53%) 214
Other cancer 0 8 (15%) 8 (15%) 36 (69%) 52
Lung cancer- Mayo study 0 137 (26%) 143 (27%) 249 (47%) 529
Lung cancer- Mayo study 6 months post diagnosis 0 326 (23%) 426 (30%) 657 (47%) 1409
Skin cancer 0 0 (0%) 4 (57%) 3 (43%) 7
Unknown site cancer 0 10 (34%) 9 (31%) 10 (34%) 29
Healthy NCCTG volunteers 0 1 (2%) 12 (22%) 41 (76%) 54
Hospice caregivers 4 9 (17%) 23 (43%) 21 (40%) 53
Hospice 5 22 (42%) 23 (44%) 7 (13%) 52
Minnesota medical students 2 84 (15%) 202 (37%) 257 (47%) 543
Mayo physicians 5 58 (13%) 174 (38%) 228 (50%) 460
Mayo residents 0 83 (28%) 125 (42%) 87 (29%) 295
Advanced cancer –psychosocial study 0 10 (23%) 24 (55%) 10 (23%) 44
NCCTG, North central chapter treatment group.
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limitation of our analyses of associations of QOL with
performance status and tumor response there was that
large amount of data were missing. The impact of data
missingness on our results is unclear and this must be
taken into account while interpreting these results. GenderTable 3 Overall QOL by age
Missing (N = 2898) <50 (N = 910) 50-64 (N = 2378)
Overall QOL
N 2884 901 2350
Mean (SD) 7.1 (2.1) 7.5 (1.9) 7.6 (1.9)
Median 7.2 8.0 8.0
Q1, Q3 6.0, 9.0 6.6, 9.0 6.8, 9.1
Range (0.0-10.0) (1.1-10.0) (0.0-10.0)
1Kruskal Wallis test.differences in reporting QOL are also nonexistent. Overall
QOL also does not automatically decline with age although
a general trend is present. Collectively these findings indi-
cate that a patient’s self-reported QOL is more than merely
a function of performance status, age, gender or any other
demographic/clinical variable.65-71 (N = 1444) 72+ (N = 1665) Total (N = 9295) p value
0.00131
1410 1616 6277
7.6 (2.0) 7.4 (2.1) 7.5 (2.0)
8.0 8.0 8.0
6.4, 9.1 6.0, 9.0 6.3, 9.0
(0.0-10.0) (0.0-10.0) (0.0-10.0)
Table 4 Overall QOL by gender
Missing (N = 2931) F (N = 2835) M (N = 3529) Total (N = 9295) p value
Overall QOL 0.251
N 2906 2772 3483 6255
Mean (SD) 7.1 (2.1) 7.6 (1.9) 7.5 (2.0) 7.5 (2.0)
Median 7.1 8.0 8.0 8.0
Q1, Q3 6.0, 9.0 6.6, 9.0 6.0, 9.0 6.3, 9.0
Range (0.0-10.0) (0.0-10.0) (0.0-10.0) (0.0-10.0)
1Kruskal Wallis test.
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but much longer, measures of quality of life in cancer
patients, there is an overriding need for simple single
item assessment measures, such as the LASA used for re-
cording overall QOL in this study [28]. This brief QOL
measure is advantageous because it reduces patient bur-
den, both in clinical situations and in clinical trials, and
has greater clinical utility for the busy practitioner [29].
Nearly 10 years ago, editors of health quality and life out-
comes indicated that there may be too many QOL assess-
ment tools, making the goal of finding an optimal tool
difficult [30], as suggested from our work published in
1998 [31]. In the text book by Fayers and Machin, section
2.5 states “the simplest and most overtly sensible approach
to measure QOL is to use global rating scales” “A global
single item measure may be a more valid measure of the
concept of interest than a score from a multi-item scale”
[32]. In a series of studies, Zimmerman et al. had almost
2,000 psychiatric outpatients complete single-item assess-
ments of psychosocial functioning and QOL, as well as
more complex measures [33]. The single item measures of
symptom severity, psychosocial functioning and QOL
were strongly correlated with the multi-item measures
and were able to discriminate among various clinical pop-
ulations, e.g., depressed and non-depressed patients. They
concluded that single-item measures could be easily incor-
porated into a busy clinical practice and were reliable and
valid in order to collect data on patient condition and
treatment effective. Similar results were found by Yohannes
et al. in patients with cystic fibrosis [34]. Krause et al. dis-
cussed the practical utility of single-item assessments [35].Table 5 Overall QOL by performance score
Missing (N = 5665) 0 (N = 1492) 1 (N
Overall QOL
N 5531 1492 1934
Mean (SD) 7.3 (2.1) 8.1 (1.7) 7.4 (2
Median 7.9 8.6 8.0
Q1, Q3 6.0, 9.0 7.4, 9.2 6.1, 9
Range (0.0-10.0) (0.0-10.0) (0.0-1
1Kruskal Wallis test.In fact, this measure is presently being used routinely in
our clinical practice for every patient visit.
Results of a survey of usage of the overall QOL item
indicate that it allows for clinicians to identify otherwise
patient concerns and to facilitate conversations regarding
the precise nature of the issues underlying the concerns
[36]. A single item can play a central role in triaging and
routine screening for issues that patients want addressed
but that have either not been raised by the clinician or
volunteered by the patient for various reasons including
lack of time in the clinical visit or discomfort surrounding
sensitive issues like sexuality [37].
The clinical importance of the single item overall QOL
is inherent in its ability to tap into the simple construct
of overall well being within a patient using his/her own
internal weighting scheme for the innumerable compo-
nent constructs [3]. While some multiple item measures
may look at many aspects of QOL, it is impossible to
cover all facets of QOL or give them appropriate weight-
ing. Indeed, it has been previously demonstrated that a
patient may report a deficit in overall QOL due to a deficit
in a single sub-domain that they consider of primary im-
portance that overrides positive indications on all other
domains [1,4]. It is this gestalt capability of a single item
that is likely the reason that it has been seem to be em-
pirically linked to overall survival. In its simplest form, the
item is asking “Do you think you are doing well?” This
even in the presence of overwhelmingly positive objective
laboratory and clinical data may be the overriding deter-
minant of the individual’s well being. In one way, this gen-
eral item can capture unknown important aspects of well= 1934) 2-3 (N = 204) Total (N = 9295) p value
<0.00011
204 3630
.0) 6.2 (2.2) 7.6 (1.9)
6.0 8.1
.0 4.8, 8.0 6.6, 9.1
0.0) (1.0-10.0) (0.0-10.0)

























N 6669 140 14 492 709 115 1022 2492
Mean (SD) 7.3 (2.1) 7.9 (1.6) 8.3 (1.4) 7.5 (2.0) 7.9 (1.8) 7.8 (1.9) 7.7 (1.8) 7.8 (1.9)
Median 7.9 8.5 8.6 8.0 8.5 8.5 8.3 8.4
Q1, Q3 6.0, 9.0 7.3, 9.1 8.0, 9.2 6.1, 9.0 7.1, 9.2 7.2, 9.2 7.0, 9.2 6.9, 9.2
Range (0.0-10.0) (2.4-9.9) (4.5-10.0) (1.0-10.0) (0.0-10.0) (1.6-10.0) (1.2-10.0) (0.0-10.0)
1Kruskal Wallis.
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clinical measures.
A major drawback and concern with the use of a simple
single-item measure of QOL is the lack of detail and pre-
cise determination of what is being measured or meant by
“overall QOL” [38]. Clearly it is not possible for any single
item to capture sufficient detail so as to delineate the
appropriate clinical pathway that should be pursued.
Its utility lies instead in the ability to differentiate
between those patients who have CSDs in the well
being that can further be explored and subsequently
treated.
Another issue with the use of an overall QOL measure
is that it may involve issues that are beyond the purview
of the clinician, such as financial or legal issues. In the
age of comprehensive, multi-disciplinary, patient-centered
care, however, identifying such issues can improve the effi-
cacy of clinical care [39]. Indeed, much has been written
about how issues beyond clinical care can impede or block
positive clinical outcomes [40,41].
The overall LASA is routinely supplemented in clinical
trials and practice by a series of other items relating to
physical mental, emotional and spiritual well-being. These
data are described elsewhere in the context of individual
studies. The purpose of presenting only the overall item
for this analysis is based on its universality and its demon-
strated linkage to survival in a wide variety of patient
populations.
Conclusions
The present study indicates that the single-item measure
of overall QOL has acceptable content and construct
validity to be used as a clinical indicator of patient well-
being. The relative capability for single items versus
multiple item PRO measures to help us understand
patient well-being is the focus of an R01-funded investi-
gation presently ongoing. This project will compare psy-
chometric properties, including the prognostic capability
for survival, among the simple LASA measures, the PRO
version of the Common Toxicity Criteria (PRO-CTCAE),
and the PROMIS. This and other studies will furtherenhance our understanding of how we may “Cross-walk”
results from alternative measures of the patient experi-
ence. Ultimately, this work will lead to a day when PROs
are routinely incorporated into clinical care as a supple-
mentary vital sign.Additional files
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